Purpose :
Venoarterial-ECMO (VA-ECMO) is indicated in the management of refractory cardiogenic shock. There is currently no risk factor for early mortality, i.e. occurring within 72 hours of implantation. Highlighting them could avoid unnecessary recourse to this costly and heavy-care technique. The objective of this study is to determine the risk factors associated with early mortality in patients implanted with VA-ECMO and to construct a prognostic score.
Methods:
This single-center retrospective study included all patients treated with VA-ECMO at Felix Guyon Hospital in Reunion Island over the period 2014-2020. The pre-implantation risk factors for early mortality were sought by logistic regression and integrated into the IMPACT score.
Results:
A total of 165 patients were included in the study. Early mortality (<72 hours) was 20% (33 patients). Four pre-implantation risk factors were identified and integrated into the IMPACT score: lactate levels > 8mmol/L (Odds ratio (OR) = 4.2; p = 0.007), platelet count < 100G/L (OR = 4.9; p = 0.022), renal replacement therapy (OR = 7.1; p = 0.001), and cardiac arrest (OR = 3.2; p = 0.036). The IMPACT score had an AUC of 0.80 [95% Confidence Interval 0.73-0.88].
Conclusion:
The IMPACT score can help the physicians to identify patients who do not expect any benefit from VA-ECMO. Its validity should be tested in other populations treated with VA-ECMO.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.